Rapid Growth and Market Penetration of BRIUMVI in MS Treatment
BRIUMVI's commercial performance exceeded expectations with US net sales of approximately $139 million in Q2 2025, a 91% YoY increase.
Nearly 1 in 3 new IV anti-CD20 MS patients are prescribed BRIUMVI, indicating strong market adoption.
The company estimates that BRIUMVI is becoming the most prescribed anti-CD20 therapy for relapsing MS, with ongoing efforts to expand its market share.
Strategic Merger of Pelthos and Channel Therapeutics
The merger involved a reverse merger process, creating a new public entity, Pelthos Therapeutics, which launched Zelsuvmi, a treatment for Molluscum contagiosum.
Pelthos's market forecast suggests capturing fewer than 100,000 patients in a 16.7 million patient market, with potential royalties of around $23 million annually in the U.S.
Ligand's strategic ownership of the nitric oxide platform and pipeline of late-stage programs offers multiple future royalty streams, emphasizing its focus on high-value assets.
Progress and Strategic Opportunities for SGR-1505 MALT1 Inhibitor
Initial Phase I data for SGR-1505 showed a well-tolerated profile with responses in heavily pretreated CLL and Waldenstrom's macroglobulinemia patients, with 3 of 17 CLL patients responding and all 5 Waldenstrom's patients responding.
The program has received FDA Fast Track designation, highlighting its potential as a promising therapeutic in refractory hematologic cancers.
Schrodinger is exploring strategic opportunities to accelerate clinical development and maximize the potential of SGR-1505, rather than pursuing independent late-stage trials.
The company plans to provide further updates on dose escalation, translational data, and regulatory feedback later this year.
The emerging profile of SGR-1505 suggests best-in-class potential, with early evidence supporting its use in refractory disease, especially in patients previously exposed to BTK and BCL2 inhibitors.
Discontinuation of M6 Artificial Disc Product Lines and Its Impact
Orthofix announced the discontinuation of the M6 artificial cervical and lumbar disc product lines in February 2025.
Pro forma results exclude M6 impact, with a focus on margin improvements driven by this discontinuation.
The discontinuation has contributed to approximately 50% of the margin expansion in Q2 2025, indicating a significant shift in product portfolio and profitability strategy.
Strategic Partnership with BioNTech for PD-L1 VEGF Bispecific BNT327
BMS entered into a global strategic partnership with BioNTech to co-develop and commercialize BNT327, a potentially transformative PD-L1 VEGF bispecific therapy.
The collaboration aims to accelerate clinical trials, expedite time to market, and expand indications, with the goal of positioning BNT327 as a first or second to market in its class.
The partnership leverages BMS' expertise in immuno-oncology and BioNTech's innovation, with a focus on speed to market and broadening indications.
Initial clinical development is underway in small cell lung cancer, non-small cell lung cancer, and triple-negative breast cancer.
Progress and Pipeline Advancements with Notable Regulatory Approvals
AbbVie received FDA approval for EMRELIS in non-squamous non-small cell lung cancer and Rinvoq for GCA, marking significant milestones in oncology and rheumatology.
The company announced positive Phase III results for Rinvoq in alopecia areata, demonstrating superior efficacy with 54% of patients reaching 80% scalp coverage at 24 weeks.
Regulatory submission of TrenibotE, a first-in-class short-acting toxin for aesthetics, is underway, with potential to expand AbbVie's aesthetic portfolio.
Strategic Focus on Phase III Readouts and Clinical Progress
The company is actively progressing towards multiple pivotal Phase III trials, including in myelofibrosis and endometrial cancer, with top-line data expected in 2026.
There is a strong emphasis on the potential of selinexor in combination with ruxolitinib to redefine the standard of care for myelofibrosis, with an estimated peak revenue potential of up to $1 billion annually in the U.S.
Management highlighted the significance of recent enrollment milestones, such as closing new patient screening for the SENTRY trial in myelofibrosis, which is a key step in their clinical development strategy.
The company is leveraging its clinical data to support regulatory and commercial ambitions, emphasizing the potential for selinexor to address unmet needs in diseases with limited treatment options.
Dafinchi
